Patents by Inventor Irène Baccelli

Irène Baccelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230357221
    Abstract: Heterocyclic compounds of Formula I: and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed.
    Type: Application
    Filed: June 28, 2023
    Publication date: November 9, 2023
    Inventors: Yves GAREAU, Stéphane GINGRAS, Yves CHANTIGNY, Gaoqiang YANG, Guy SAUVAGEAU, Irène BACCELLI, Anne MARINIER
  • Patent number: 11760754
    Abstract: Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: September 19, 2023
    Assignee: UNIVERSITÉ DE MONTRÉAL
    Inventors: Yves Gareau, Stéphane Gingras, Yves Chantigny, Gaoqiang Yang, Guy Sauvageau, Irène Baccelli, Anne Marinier
  • Publication number: 20230227565
    Abstract: New clinical uses of anti-CD127 agents, in particular anti-CD127 antibodies or related compounds for the treatment and/or the prevention of cancer. Methods for treating a patient having a CD127-positive cancer are provided, in particular a CD127-positive leukemia or a CD127-positive solid tumor, by administering to the patient a therapeutic dose of an anti-CD127 agent, the anti-CD127 agent having the capability to enhance the Antibody Dependent Cellular Phagocytosis (ADCP) activity of macrophages targeting CD127-positive cancer cells, and not having Antibody Dependent Cytotoxic Activity (ADCC), in particular against immune cells, more particularly against T cells.
    Type: Application
    Filed: November 30, 2022
    Publication date: July 20, 2023
    Inventors: Nicolas POIRIER, Irène BACCELLI, Caroline MARY, Sabrina PENGAM
  • Publication number: 20220389104
    Abstract: The invention pertains to the field of immunotherapy. The present invention provides a new use of anti-CD127 agent, in particular anti-CD127 antibodies or related compounds for the treatment and/or the prevention of cancer. The invention relates to a method for treating a patient having a CD127-positive cancer, in particular a CD127-positive leukemia, by administering to the patient a therapeutic dose of an anti-CD127 agent, the anti-CD127 agent having the capability to enhance the Antibody Dependent Cellular Phagocytosis (ADCP) activity of macrophages targeting CD127-positive cancer cells, and that does not have Antibody Dependent Cytotoxic Activity (ADCC), in particular on immune cells, more particularly on T cells.
    Type: Application
    Filed: May 28, 2021
    Publication date: December 8, 2022
    Inventors: Nicolas POIRIER, Irène BACCELLI, Caroline MARY, Sabrina PENGAM
  • Publication number: 20210387980
    Abstract: Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed.
    Type: Application
    Filed: November 2, 2018
    Publication date: December 16, 2021
    Inventors: Yves Gareau, Stéphane Gingras, Yves Chantigny, Gaoqiang Yang, Guy Sauvageau, Irène Baccelli, Anne Marinier
  • Publication number: 20200188361
    Abstract: A method for treating acute myeloid leukemia (AML), such as poor risk AML, by administering to a subject in need thereof an effective amount of a mitochondrial activity inhibitor, for example a class A electron transport chain (ETC) complex I inhibitor such as Mubritinib or a pharmaceutically acceptable salt thereof, is disclosed. The AML to be treated may be characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (NK), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDII1, mutated IDII2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.
    Type: Application
    Filed: January 24, 2020
    Publication date: June 18, 2020
    Applicant: UNIVERSITE DE MONTREAL
    Inventors: Guy Sauvageau, Irene Baccelli
  • Publication number: 20190192488
    Abstract: A method for treating acute myeloid leukemia (AML), such as poor risk AML, by administering to a subject in need en thereof an effective amount of a mitochondrial activity inhibitor, for example a class A electron transport chain (ETC) complex I inhibitor such as Mubritinib or a pharmaceutically acceptable salt thereof, is disclosed. The AML to be treated may be characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (NK), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT 1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.
    Type: Application
    Filed: August 1, 2017
    Publication date: June 27, 2019
    Applicant: Université de Montréal
    Inventors: Guy SAUVAGEAU, Irène BACCELLI
  • Publication number: 20180120320
    Abstract: This invention relates to a novel method for analyzing circulating tumor cells of a patient for the presence of metastasis-initiating cells. The method comprises the step of detecting cells exhibiting the simultaneous presence of c-MET, CD44 and CD47. The invention further relates to novel kits, novel methods for treating patients, and novel bifunctional analytes.
    Type: Application
    Filed: October 27, 2017
    Publication date: May 3, 2018
    Inventors: Andreas Trumpp, Irène Baccelli
  • Publication number: 20130236890
    Abstract: This invention relates to a novel method for analyzing circulating tumor cells of a patient for the presence of metastasis-initiating cells. The method comprises the step of detecting cells exhibiting the simultaneous presence of c-MET, CD44 and CD47. The invention further relates to novel kits, novel methods for treating patients, and novel bifunctional analytes.
    Type: Application
    Filed: March 8, 2012
    Publication date: September 12, 2013
    Applicant: HI-STEM Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH
    Inventors: Andreas Trumpp, Irène Baccelli